



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet

1

of

1

Complete if Known	
Application Number	09/991,971
Filing Date	26 November 2001
First Named Inventor	Markku AHOTUPA
Group Art Unit	1644
Examiner Name	P.N. Huynh
Attorney Docket Number	2630-113

RECEIVED

AUG 18 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
PNK	1	EP	0 906 761	A2	Archer Daniels Midland Company	07 April 1999	
PNK	2	WO	02/080702	A1	Unilever N.V. et al.	17 October 2002	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PNK	3	CHO, Jae Youl et al. (1999). "Immunomodulatory Effect of Arctigenin, a Lignan Compound, on Tumour Necrosis Factor-alpha and Nitric Oxide Production and Lymphocyte Proliferation," <i>J. Pharm. Pharmacol.</i> 51:1267-1273.	
	4	YANG, Li-Ming et al. (1996). "Synthesis and Anti-HIV Activity of Dibenzylbutyrolactone Lignans," <i>Bioorganic & Medicinal Chem. Letts.</i> 6(8):941-944.	
	5	CHO, Min Kyung et al. (2002). "Potent Inhibition of Lipopolysaccharide-Inducible Nitric Oxide Synthase Expression by Dibenzylbutyrolactone Lignans Through Inhibition of I-kappa Balpha Phosphorylation and of p65 Nuclear Translocation in Macrophages," <i>Intl. Immunopharmacol.</i> 2:105-116.	
↓	6	HIRANO, Toshihiko et al. (1994). "Natural Flavonoids and Lignans are Potent Cytostatic Agents Against Human Leukemic HL-60 Cells," <i>Life Sciences</i> 55(13):1061-1069.	

Examiner Signature	Date Considered
<i>PNK</i>	12/12/03

***EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.